eXoZymes, Inc.
NASDAQ:EXOZBiotechnology
Healthcare
$5.54 +16.75%
+$1.06 today
- Market cap
- $51.42M
- Beta
- 2.66
- P/E (TTM)
- -6.5
- EPS (TTM)
- -$1.14
52W Low $6.33High $18.40
Volume 0.01M
Average 0.01M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$6.50M
FY 2025 · Annual
Investing Cash Flow
-$150,218.00
FY 2025 · Annual
Financing Cash Flow
-$27,709.00
FY 2025 · Annual
Cash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (1.21M) | (1.4M) | (2.04M) | (5.86M) | (9.16M) |
| Depreciation & Amortization | 59.41K | 147.75K | 196.94K | 267.38K | (52.91K) |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 198.46K | 216.5K | 281.54K | 1.13M | 1.99M |
| Change in Working Capital | (536.48K) | (190.07K) | 220.31K | (4.02M) | 380.17K |
| Accounts Receivables | (317.07K) | (341.18K) | (72.79K) | 145.04K | 114.72K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (214.43K) | 118.5K | 272.89K | 221.34K | 311.09K |
| Other Working Capital | (4.99K) | 32.61K | 20.21K | (4.38M) | (45.63K) |
| Other Non-Cash Items | (99K) | (35.15K) | 158.73K | (19.4K) | 341.33K |
| Operating Cash Flow | (1.59M) | (1.26M) | (1.18M) | (8.51M) | (6.5M) |
| Capital Expenditures | (422.59K) | (185.98K) | (288.71K) | (396.45K) | (169.92K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 110.33K | 98.77K | (22.46K) | 37.24K | 19.7K |
| Investing Cash Flow | (312.25K) | (87.21K) | (311.17K) | (359.22K) | (150.22K) |
| Debt Repayment | 0 | 0 | 0 | 3.98M | (27.71K) |
| Common Stock Issued | 2.31M | 1.36M | 0 | 14.53M | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 1M | 11.82K | 0 |
| Financing Cash Flow | 2.31M | 1.36M | 1M | 18.52M | (27.71K) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 413.45K | 10.76K | (492.04K) | 9.65M | (6.68M) |
| Free Cash Flow | (2.01M) | (1.44M) | (1.47M) | (8.9M) | (6.67M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$9.2M
+ D&A-$52.9K
+ Stock-Based Comp$2.0M
+ Deferred Tax$0
+ Working Capital$380.2K
+ Other Non-Cash$341.3K
= Operating Cash Flow-$6.5M
- Capex-$169.9K
= Free Cash Flow-$6.7M
Analysis
FY2025 free cash flow is -$6.7M. FCF conversion is 72.8% of net income. Operating cash flow was -$6.5M, with capex of -$169.9K. The largest bridge item is Stock-Based Comp at $2.0M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Sep 18, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 17, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 2, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 25, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 25, 2026 |
Does EXOZ generate free cash flow?
eXoZymes, Inc. (EXOZ) generated -$6.67M of free cash flow in fiscal 2025.
How much operating cash flow does EXOZ produce?
Operating cash flow was -$6.50M, before capital expenditures of $169,917.00.
Continue the stock analysis
Jump to another research area for this company.